Scinai Immunotherapeutics Ltd.
SCNI
$2.44
-$0.0734-2.92%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -174.99% | 182.59% | -7.03% | -7.03% | -- |
| Total Depreciation and Amortization | -42.07% | -1.36% | 6.52% | 6.52% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -159.75% | 3.69% | -144.74% | -16.85% | -- |
| Change in Net Operating Assets | 190.51% | -328.40% | 183.26% | 37.59% | -- |
| Cash from Operations | 44.87% | 22.74% | 5.98% | 5.98% | -- |
| Capital Expenditure | -1,070.00% | 94.69% | -6,183.33% | -6,183.33% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,070.00% | 94.69% | -6,183.33% | -6,183.33% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -300.00% | 117.07% | 81.70% | 81.70% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.20% | 65.12% | -0.15% | -0.15% | -- |